新生血管性年龄相关性黄斑变性患者接受玻璃体腔血管内皮生长因子抑制剂治疗的现实世界结局
玻璃体腔抗血管内皮生长因子(anti-VEGF)药物治疗新生血管性年龄相关性黄斑变性(AMD)在临床试验中可稳定或改善视力,现实世界证据用于评估随机对照试验结果能否外推至一般人群。本文描述了全球登记系统(尤其澳大利亚的Fight Retinal Blindness!登记系统、英国AMD电子病历用户组和美国IRIS登记系统)的发展,总结了抗VEGF治疗新生血管性AMD在疗效、安全性和资源利用方面的现实世界观察,并强调了临床试验中难以发现的新观察,最后探讨未来方向。
要点
- 现实世界登记系统可评估抗VEGF治疗新生血管性AMD的疗效、安全性和资源利用。
- 临床试验中难以发现的新观察包括晚期疾病再激活风险、第二只眼与第一只眼治疗结局差异、以及接受抗VEGF治疗后白内障手术中后囊膜破裂风险增加。
- 未来方向包括建立现实世界结局指标的全球共识、登记系统与其他数据库链接、机器学习提取大数据信息,以及作为4期临床试验替代方案供监管机构和产业界使用。
核心结论
- 本文总结现实世界观察以评估抗VEGF治疗新生血管性AMD的疗效、安全性和资源利用,并强调临床试验中难以发现的新观察及未来方向。
研究设计与样本
- 本文为综述,描述全球登记系统的发展并总结现实世界观察,未报告检索范围、样本量或研究类型。
主要发现
- 现实世界观察涉及抗VEGF治疗新生血管性AMD的疗效、安全性和资源利用。
- 新观察包括晚期疾病再激活风险、第二只眼与第一只眼治疗结局差异,以及接受抗VEGF治疗后白内障手术中后囊膜破裂风险增加。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF agents) have the potential to stabilise or even improve visual acuity outcomes in neovascular age-related macular degeneration (AMD), a sight-threatening disease. Real-world evidence allows us to assess whether results from randomised controlled trials can be applied to the general population. We describe the development of global registries, in particular the Fight Retinal Blindness! registry that originated in Australia, the United Kingdom AMD Electronic Medical Records User Group and the IRIS registry in the USA. Real-world observations relating to efficacy, safety and resource utilisation of intravitreal anti-VEGF therapy for neovascular AMD are then summarised. Novel observations that would have been challenging to identify in a clinical trial setting are then highlighted, including the risk of late disease reactivation, outcomes in second versus first treated eyes, and the increased risk of posterior capsular rupture during cataract surgery in patients who have received intravitreal anti-VEGF therapy. We conclude by exploring future directions in the field. This includes the development of a global consensus on real-world outcome measures to allow greater comparison of results. Real-world neovascular AMD outcome registries can be linked with other databases to determine systemic safety or genetic predictors of treatment efficacy. Machine learning offers opportunities to extract useful insights from "Big Data" often collected in these registries. Real-world registries could be used by drug regulatory authorities and industry as an alternative to more costly and time-consuming phase 4 clinical trials, potentially allowing medication costs to be based on outcomes achieved.
引用
- Mehta H, Tufail A, Daien V, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018. PMID: 29305324. doi:10.1016/j.preteyeres.2017.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。